Identification of a novel competing endogenous RNA network linked to the prognosis of prostate cancer

Author:

Ma Luping1,Song Yongcheng1,Li Changtao1,Li Qiang1,Huang Qianqian1,Liang Weihua1,Wang Chengyan1,Wang Qinzhang1

Affiliation:

1. Shihezi University, Shihezi University School of Medicine

Abstract

Abstract According to mounting evidence, competing endogenous RNAs (ceRNA) play a significant role in the tumorigenesis and development of cancer. Prostate cancer (PCa) is a common malignancy among men. Nevertheless, reliable indicators for the early diagnosis and prognosis of Pca are still lacking. Therefore, this study aimed to identify competing endogenous RNA networks as novel prognostic predictors of PCa. The Cancer Genome Atlas was used to download the RNA transcriptome and clinical data of 498 Pca and 52 non-Pca tissues. Differentially expressed messenger RNAs (DEmRNAs) were identified using the edgeR package. Kaplan–Meier analysis was used to evaluate the correlation with survival. TargetScan and MiRDB were used to predict potential DRD5‒targeting microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). In addition, StarBase and GEPIA2 were used to validate regulatory and prognostic relationships. DEmRNAs, target miRNAs, and lncRNAs were identified, and a ceRNA network in PCa was constructed. A total of 1,603 Pca-specific differentially expressed genes (767 upregulated and 836 downregulated) were identified. In addition, 3 hub mRNAs, 26 miRNAs,and 2 lncRNAs were identified as a result of stepwise prediction and validation from mRNA to lncRNA. Finally, C9orf170/hsa-miR-153-5p/DRD5 was identified as a prognosis-related network in PCa through further screening. In this study, we constructed a novel ceRNA network in PCa in which each component was prognosis-related.

Publisher

Research Square Platform LLC

Reference43 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2021

2. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis;Yuan X;Oncogene.,2014

3. Hormonal therapy for prostate cancer;Desai K;Endocr Rev,2021

4. Prostate cancer;Rebello RJ;Nat Rev Dis Primers,2021

5. Drug resistance in castration resistant prostate cancer: Resistance mechanisms and emerging treatment strategies;Armstrong CM;Am J Clin Exp Urol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3